SEC Form 4/A · accession 0002111813-26-000008
Faeth Therapeutics, Inc. · FTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Anand Kiran Parikh
Officer — President and CEO · Director
Period of report
Feb 17, 2026
Accepted (ET)
Jun 16, 2026 · 4:16 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001829802
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred StockF2,F3,F1 | — | Feb 17, 2026 | A | 761 | A | — | — | Common Stock | 761,428 | 761,428 | D |
| Employee Stock Option (right to buy)F4,F5 | $1.16 | Feb 17, 2026 | A | 12,320 | A | — | Sep 14, 2032 | Common Stock | 12,320 | 12,320 | D |
| Employee Stock Option (right to buy)F6,F7 | $1.16 | Feb 17, 2026 | A | 136,884 | A | — | Nov 30, 2025 | Common Stock | 136,884 | 136,884 | D |
Explanation of responses
- F1Each share of Series B Non-Voting Convertible Preferred Stock (the "Series B Preferred Stock") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the "Company"). The Preferred Stock has no expiration date.
- F2Received in exchange for 4,062,777 shares of common stock of Faeth Holdings Therapeutics, Inc. ("HoldCo") pursuant to an Agreement and Plan of Merger, dated February 17, 2026 (the "Merger Agreement"), by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Second Merger Sub"), HoldCo and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth").
- F3Under the terms of the Merger Agreement, on February 17, 2026, First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the "Merger"). Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Company's Series B Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Company's Common Stock ("Common Stock").
- F4Received in exchange for a stock option to acquire an aggregate 61,809 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement.
- F5Beginning August 1, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.
- F6Received in exchange for stock options to acquire an aggregate of 686,733 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement.
- F7Beginning on March 1, 2026, 12,258 shares vest monthly through January 1, 2027, with the balance fully vesting on February 1, 2027.
Remarks
This amendment corrects the previously reported transactions on Form 4 filed February 19, 2026, to disclose the correct number of shares included in the option awards and the correct number of shares of Series B Preferred Stock